Anti-TLR2 antibody (KO Validated)
Specifications
| Product Cat#: | AB-06-4368 |
| Product type: | Primary antibody |
| Antigen: | TLR2 |
| Immunogen: | Recombinant protein within human TLR2 aa 21-588 (Extracellular). |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:400-1:2000); Immunohistochemistry-Paraffin (1:40-1:200); Flow Cytometry (1:40-1:100); Immunocytochemistry/Immunofluorescence (1:40-1:200) |
| Reactivity: | Human, Mouse, Rat |
| Clonality (clone number): | Monoclonal, [JM22-41] |
| Form: | Liquid |
| Buffer: | Tris-HCl buffer (pH 7.4), 0.05% BSA, 40% glycerol, 0.05% NaN3. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | CD282 antibody |
| CD282 antigen antibody | |
| TIL 4 antibody | |
| TIL4 antibody | |
| TLR 2 antibody | |
| TLR2 antibody | |
| TLR2_HUMAN antibody | |
| Toll like receptor 2 antibody | |
| Toll like receptor 2 precursor antibody | |
| Toll-like receptor 2 antibody | |
| Toll/interleukin 1 receptor like 4 antibody | |
| Toll/interleukin 1 receptor like protein 4 antibody | |
| Toll/interleukin receptor like protein 4 antibody | |
| Toll/interleukin-1 receptor-like protein 4 antibody |
Target information
Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also activate immune cells and promote apoptosis in response to the lipid moiety of lipoproteins. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6. Stimulation of monocytes in vitro with M.tuberculosis PstS1 induces p38 MAPK and ERK1/2 activation primarily via this receptor, but also partially via TLR4. MAPK activation in response to bacterial peptidoglycan also occurs via this receptor.
Provider
Erpantech Laboratory